EP3856148A4 - Formulation pharmaceutique contenant un sélénite triglycéride et un agent cytostatique destinée à être utilisée dans le traitement d'une tumeur - Google Patents

Formulation pharmaceutique contenant un sélénite triglycéride et un agent cytostatique destinée à être utilisée dans le traitement d'une tumeur Download PDF

Info

Publication number
EP3856148A4
EP3856148A4 EP19865889.0A EP19865889A EP3856148A4 EP 3856148 A4 EP3856148 A4 EP 3856148A4 EP 19865889 A EP19865889 A EP 19865889A EP 3856148 A4 EP3856148 A4 EP 3856148A4
Authority
EP
European Patent Office
Prior art keywords
selenitetriglyceride
cytostatic
tumour
treatment
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19865889.0A
Other languages
German (de)
English (en)
Other versions
EP3856148A2 (fr
Inventor
Katarzyna WIKTORSKA
Lidia Mielczarek
Zdzis aw CHILMONCZYK
Piotr Suchocki
Pamela Krug
Maciej Mazur
Paulina G OWALA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Narodowy Inst Lekow W Warszawie
Narodowy Instytut Lekow W Warszawie
Univ Warszawski Medyczny
Uniwersytet Warszawski
Warszawski Uniwersytet Medyczny
Original Assignee
Narodowy Inst Lekow W Warszawie
Narodowy Instytut Lekow W Warszawie
Univ Warszawski Medyczny
Uniwersytet Warszawski
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Narodowy Inst Lekow W Warszawie, Narodowy Instytut Lekow W Warszawie, Univ Warszawski Medyczny, Uniwersytet Warszawski, Warszawski Uniwersytet Medyczny filed Critical Narodowy Inst Lekow W Warszawie
Publication of EP3856148A2 publication Critical patent/EP3856148A2/fr
Publication of EP3856148A4 publication Critical patent/EP3856148A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19865889.0A 2018-09-27 2019-09-26 Formulation pharmaceutique contenant un sélénite triglycéride et un agent cytostatique destinée à être utilisée dans le traitement d'une tumeur Pending EP3856148A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL427216A PL241189B1 (pl) 2018-09-27 2018-09-27 Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworów
PCT/PL2019/050055 WO2020067910A2 (fr) 2018-09-27 2019-09-26 Formulation pharmaceutique contenant un sélénite triglycéride et un agent cytostatique destinée à être utilisée dans le traitement d'une tumeur

Publications (2)

Publication Number Publication Date
EP3856148A2 EP3856148A2 (fr) 2021-08-04
EP3856148A4 true EP3856148A4 (fr) 2022-06-15

Family

ID=69953584

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19865889.0A Pending EP3856148A4 (fr) 2018-09-27 2019-09-26 Formulation pharmaceutique contenant un sélénite triglycéride et un agent cytostatique destinée à être utilisée dans le traitement d'une tumeur

Country Status (3)

Country Link
EP (1) EP3856148A4 (fr)
PL (1) PL241189B1 (fr)
WO (1) WO2020067910A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113713110B (zh) * 2021-09-22 2022-11-15 滨州医学院 一种药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL229503B1 (pl) * 2015-09-21 2018-07-31 Narodowy Inst Lekow Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów
WO2020050731A1 (fr) * 2018-09-04 2020-03-12 Narodowy Instytut Leków W Warszawie Combinaison d'isothiocyanates avec des composés organiques de sélénium encapsulés dans des vecteurs de médicament en tant que nouveaux agents pharmaceutiques ayant une activité antitumorale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107714650A (zh) * 2016-08-11 2018-02-23 杭州健昵福生物科技有限公司 一种含谷氨酰胺代谢抑制剂脂质体及其药物组合物与用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL229503B1 (pl) * 2015-09-21 2018-07-31 Narodowy Inst Lekow Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów
WO2020050731A1 (fr) * 2018-09-04 2020-03-12 Narodowy Instytut Leków W Warszawie Combinaison d'isothiocyanates avec des composés organiques de sélénium encapsulés dans des vecteurs de médicament en tant que nouveaux agents pharmaceutiques ayant une activité antitumorale

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARMELA FIMOGNARI ET AL: "Sulforaphane Modulates Cell Cycle and Apoptosis in Transformed and Non-transformed Human T Lymphocytes", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1010, no. 1, 24 January 2006 (2006-01-24), pages 393 - 398, XP071398685, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1299.072 *
DUDKIEWICZ-WILCZYNSKA JADWIGA ET AL: "Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol", WSPÓŁCZESNA ONKOLOGIA, vol. 2, 1 January 2014 (2014-01-01), pages 90 - 94, XP055917752, ISSN: 1428-2526, DOI: 10.5114/wo.2014.40558 *
DUDKIEWICZ-WILCZYNSKA JADWIGA ET AL: "The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions", PLOS ONE, vol. 11, no. 5, 19 May 2016 (2016-05-19), pages e0155772, XP055461801, DOI: 10.1371/journal.pone.0155772 *
GLUZ O. ET AL: "Triple-negative breast cancer-current status and future directions", ANNALS OF ONCOLOGY, vol. 20, no. 12, 1 December 2009 (2009-12-01), NL, pages 1913 - 1927, XP055918026, ISSN: 0923-7534, DOI: 10.1093/annonc/mdp492 *
LOPES SILVIA ET AL: "Interaction of 5-Fluorouracil Loaded Nanoparticles with 1,2-Dimyristoyl- sn -glycero-3-phosphocholine Liposomes Used as a Cellular Membrane Model", JOURNAL OF PHYSICAL CHEMISTRY PART B, vol. 116, no. 1, 28 December 2011 (2011-12-28), US, pages 667 - 675, XP055918020, ISSN: 1520-6106, DOI: 10.1021/jp210088n *
RAYANE GANASSIN ET AL: "Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro", ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY, 27 November 2017 (2017-11-27), pages 1 - 11, XP055706047, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/21691401.2017.1408020> [retrieved on 20200617], DOI: 10.1080/21691401.2017.1408020 *

Also Published As

Publication number Publication date
PL241189B1 (pl) 2022-08-22
PL427216A1 (pl) 2020-04-06
WO2020067910A3 (fr) 2020-05-14
EP3856148A2 (fr) 2021-08-04
WO2020067910A2 (fr) 2020-04-02

Similar Documents

Publication Publication Date Title
EP3471735A4 (fr) Compositions pharmaceutiques et leur utilisation pour le traitement du cancer et des maladies auto-immunes
EP3777888A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
EP3813853A4 (fr) Compositions pour l&#39;administration de médicaments et leurs méthodes d&#39;utilisation
EP3694832A4 (fr) Formulation pharmaceutique à libération prolongée et procédés de traitement
EP3607952A4 (fr) Utilisation de carrimycine et d&#39;un sel pharmaceutiquement acceptable de celle-ci pour la fabrication d&#39;un médicament pour le traitement et/ou la prévention de tumeurs
EP3526195A4 (fr) Sulfoxyalkyle organonitro, composés apparentés et compositions pharmaceutiques destinées à être utilisées en médecine
EP3858353A4 (fr) Composition pharmaceutique pour prévenir et traiter la nitm et utilisation pharmaceutique associée
EP3639829A4 (fr) Utilisation de l&#39;isovalérylspiramycine i, ii et/ou iii dans la préparation d&#39;un médicament pour le traitement et/ou la prévention d&#39;une tumeur, et un médicament
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3606611A4 (fr) Dispositifs portables non effractifs pour la médecine intégrative et la guérison holistique
EP3566710A4 (fr) Agent thérapeutique et son application dans des médicaments pour le traitement de tumeurs et/ou du cancer
EP4066837A4 (fr) Utilisation de bi853520 dans le traitement du cancer
EP3525791A4 (fr) Utilisation d&#39;inhibiteurs de caspase-3 et d&#39;activateurs de caspase-3 dans la fabrication d&#39;un médicament pour le traitement du cancer et de la cicatrisation des plaies
EP3468540A4 (fr) Compositions pharmaceutiques et méthodes de traitement du cancer
EP3856148A4 (fr) Formulation pharmaceutique contenant un sélénite triglycéride et un agent cytostatique destinée à être utilisée dans le traitement d&#39;une tumeur
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3881843A4 (fr) Agent prophylactique ou thérapeutique et composition médicinale contre une maladie à médiation par l&#39;il-31
EP3753579A4 (fr) Conjugué toxine-anticorps anti-trailr2 et son utilisation pharmaceutique en thérapie anti-tumorale
EP3777849A4 (fr) Composition pharmaceutique, comprenant du polmacoxib et de la prégabaline, pour le traitement de la douleur
HK1259382A1 (zh) 藥物製劑及其用於治療色素性視網膜炎的用途
EP3458058A4 (fr) Composition pharmaceutique et son utilisation dans le traitement de maladies auto-immunes
EP3406626A4 (fr) Peptide pour traitement du cancer, et composition pharmaceutique contenant celui-ci
EP3838270A4 (fr) Composition pharmaceutique synergique d&#39;acéclofénac et de bétaméthasone pour le traitement de la douleur dans les formes localisées d&#39;affections rhumatismales
EP3362096A4 (fr) Composition de traitement ophtalmique et véhicule pour l&#39;administration de substances pharmaceutiques ou d&#39;agents thérapeutiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210426

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009127000

Ipc: A61K0031330000

A4 Supplementary search report drawn up and despatched

Effective date: 20220513

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 33/04 20060101ALI20220510BHEP

Ipc: A61K 31/375 20060101ALI20220510BHEP

Ipc: A61K 31/357 20060101ALI20220510BHEP

Ipc: A61P 35/00 20060101ALI20220510BHEP

Ipc: A61K 9/127 20060101ALI20220510BHEP

Ipc: A61K 31/704 20060101ALI20220510BHEP

Ipc: A61K 31/513 20060101ALI20220510BHEP

Ipc: A61K 31/33 20060101AFI20220510BHEP